Skip to main content
. 2014 Aug 4;12(6):681–691. doi: 10.1038/cmi.2014.59

Figure 5.

Figure 5

CYM inhibits monocyte migration by reducing the production of CCL2 and CCL7 by endothelial cells. (a, b) HUVECs were treated by 0.1 µM or 1 µM CYM or an equal volume of DMSO for 24 h, and mRNA expressions of CCL2 and CCL7 were analyzed. (c) Monocytes from the peripheral blood were sorted and treated with the CCR2 antagonist RS102895 or control media. They were placed in the upper wells in the transwell assay with CYM-treated or control-treated HUVEC supernatant placed in the lower wells. (d, e) The serum levels of CCL2 and CCL7 were analyzed day 4 post BMT. The data are representative of five independent experiments. Data are shown as the mean±s.e.m. (*P<0.05, **P<0.01). BMT, bone marrow transplantation; HUVEC, human umbilical vein endothelial cell.